Radiomics is leading a clinical trial entitled "SALMON" ("meaSure lung cAncer bioLogy and treatMent respOnse via imagiNg"), a prospective, interventional, multi-center, multi-country, biomarker validation study, involving 30 healthcare institutions within the EU and the US, to demonstrate the value of AI solutions in 1000 patients with non-small cell lung cancer.
 
 
Radiomics other areas

 

 

onetrial, threetracks, multiplevaluable solutions

SALMON study tracks


 

*for further information, please contact us
 

This study has received funding from SPWand DG06

DGO6

SPW